Sign in
4

Changes in Ownership

CRISPR Therapeutics AG Filed Acc 0000899243-19-006647

Options or other derivatives

  • Chief Executive Officer acquired 250,000 shares (grant or award)

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I
Derivatives
Kulkarni Samarth Chief Executive Officer 2019-03-05 Grant or award · Stock Option (Right to Buy) +250,000 250,000 D
Loading xslF345X03/doc4.xml…